Tags

Type your tag names separated by a space and hit enter

[Pharmacotherapeutics for the New Coronavirus Pneumonia].
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 14; 43(0):E012.ZJ

Abstract

The New Coronavirus Pneumonia (NCP, also named as COVID-19 by WHO on Feb 11 2020, is now causing a severe public health emergency in China since. The number of diagnosed cases is more than 40,000 until the submission of this manuscript. Coronavirus has caused several epidemic situations world widely, but the present contagious disease caused by 2019 new Coronavirus is unprecedentedly fulminating. The published cohorts of 2019 new Coronavirus (n-Cov) are single-center studies, or retrospective studies. We here share the therapeutic experiences of NCP treatment with literature review. Combination of Ribavirin and Interferon-α is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable. Systemic glucocorticosteroid is recommended as a short term use (1~2 mg.kg(-1).d(-1), 3~5d) by the 5(th) edition National Health Commission's Regimen (Revised Edition) yet RCTs are expected to confirm the effectiveness. Inappropriate application of antibiotics should be avoided, especially the combination of broad-spectrum antibiotics, for the NCP is not often complicated with bacterial infection.

Authors+Show Affiliations

Medical ICU, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100730, China.Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.

Pub Type(s)

English Abstract
Journal Article

Language

chi

PubMed ID

32057209

Citation

Du, B, et al. "[Pharmacotherapeutics for the New Coronavirus Pneumonia]." Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases, vol. 43, no. 0, 2020, pp. E012.
Du B, Qiu HB, Zhan X, et al. [Pharmacotherapeutics for the New Coronavirus Pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(0):E012.
Du, B., Qiu, H. B., Zhan, X., Wang, Y. S., Kang, H. Y. J., Li, X. Y., Wang, F., Sun, B., & Tong, Z. H. (2020). [Pharmacotherapeutics for the New Coronavirus Pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases, 43(0), E012. https://doi.org/10.3760/cma.j.issn.1001-0939.2020.0012
Du B, et al. [Pharmacotherapeutics for the New Coronavirus Pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 14;43(0):E012. PubMed PMID: 32057209.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Pharmacotherapeutics for the New Coronavirus Pneumonia]. AU - Du,B, AU - Qiu,H B, AU - Zhan,X, AU - Wang,Y S, AU - Kang,H Y J, AU - Li,X Y, AU - Wang,F, AU - Sun,B, AU - Tong,Z H, Y1 - 2020/02/14/ PY - 2020/2/15/entrez KW - Antibiotics KW - Glucocorticosteroid KW - New coronavirus pneumonia KW - Pharmacotherapeutics SP - E012 EP - E012 JF - Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases JO - Zhonghua Jie He He Hu Xi Za Zhi VL - 43 IS - 0 N2 - The New Coronavirus Pneumonia (NCP, also named as COVID-19 by WHO on Feb 11 2020, is now causing a severe public health emergency in China since. The number of diagnosed cases is more than 40,000 until the submission of this manuscript. Coronavirus has caused several epidemic situations world widely, but the present contagious disease caused by 2019 new Coronavirus is unprecedentedly fulminating. The published cohorts of 2019 new Coronavirus (n-Cov) are single-center studies, or retrospective studies. We here share the therapeutic experiences of NCP treatment with literature review. Combination of Ribavirin and Interferon-α is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable. Systemic glucocorticosteroid is recommended as a short term use (1~2 mg.kg(-1).d(-1), 3~5d) by the 5(th) edition National Health Commission's Regimen (Revised Edition) yet RCTs are expected to confirm the effectiveness. Inappropriate application of antibiotics should be avoided, especially the combination of broad-spectrum antibiotics, for the NCP is not often complicated with bacterial infection. SN - 1001-0939 UR - https://www.unboundmedicine.com/medline/citation/32057209/[Pharmacotherapeutics_for_the_New_Coronavirus_Pneumonia] L2 - http://journal.yiigle.com/LinkIn.do?linkin_type=pubmed&DOI=10.3760/cma.j.issn.1001-0939.2020.0012 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.